Predictive Biotech, Inc., a Salt Lake City, UT life sciences company formed in 2015, is a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s jelly umbilical cord-derived products.

Learn More

Products

AmnioCyte™ is a minimally manipulated human tissue allograft derived from amniotic fluid. AmnioCyte™ is processed to preserve the cytokines, growth factors and proteins in amniotic fluid for homologous use.

AmnioCyte Plus™ is a minimally manipulated human tissue allograft derived from the extracellular matrix of the amniotic membrane. AmnioCyte Plus™ is processed to preserve cytokines, growth factors and scaffolding proteins in amniotic membrane for homologous use.

PolyCyte™ is a minimally manipulated human tissue allograft derived from the Wharton’s jelly of the umbilical cord. PolyCyte™ is processed to preserve cytokines, growth factors, proteins and structural integrity of Wharton’s jelly for homologous use.

CoreCyte™ is a minimally manipulated human tissue allograft derived from the Wharton’s jelly of the umbilical cord. CoreCyte™ is processed to preserve the structural integrity of Wharton’s jelly for homologous use and cryogenically preserved.

Predictive Laboratories focuses on clinical and discovery work for human infertility and genetic conditions affecting women and children, such as endometriosis, scoliosis and degenerative disc disease. Testing is performed using state-of-the-art instrumentation at our CAP and CLIA accredited facility. The lab is active in new test and technology development and collaborates with numerous federal, state, and local agencies, universities, commercial laboratories, and private clients.

Learn More

Diagnostics

ARTguide™ is the first, non-invasive, integrated test for endometriosis and genetic causes of infertility. Indicated for women considering the use of Assisted Reproductive Technologies (ART), this test uses next-generation sequencers to examine critical genetic variables using a proprietary algorithm. ARTguide™ provides physicians with information that is essential when creating an accurate and personalized treatment plan.

Genetics play a major role in the body’s response to medications. PGxPLUS+™ helps healthcare providers prevent adverse drug reactions by providing genomic information that informs medication selection and dosing guidance.